No abstract

No abstract

No abstract

Torre GC, Rembado R, Barbetti V, Vigliercio GP, Foglia M, Calabrese A, Corongiu F. Serum levels of tumor-associated trypsin inhibitor (TATI) in benign and malignant gynecological diseases. Scand J Clin Lab Invest 1991; 51 (Suppl. 207): 15-18.The behavior of tumor-associated trypsin inhibitor (TATI) as a marker for gynecological cancer was studied in a control population and in patients with different benign and malignant diseases. When a cut-off level of 21.4 pgll was used the specificity was 100% in patients with benign diseases. The sensitivity in patients with malignant tumors was low for cervical and corpus cancer, 13% and 14%, respectively, whereas it was 33% in all the ovarian malignant tumors, reaching 60% in the mucinous type. There was a clear correlation between TATI level and stage.

No abstract